Bulevirtide
Hepcludex (bulevirtide) is a protein pharmaceutical. Bulevirtide was first approved as Hepcludex on 2020-07-31. It has been approved in Europe to treat chronic hepatitis d.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
No data
Labels
FDA
EMA
No data
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
HCPCS
No data
Clinical
Clinical Trials
24 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Hepatitis d | D003699 | EFO_0007304 | — | 2 | 5 | 3 | — | 11 | 20 |
| Hepatitis | D006505 | — | K75.9 | 2 | 6 | 2 | — | 6 | 14 |
| Hepatitis a | D006506 | EFO_0007305 | B15 | 2 | 5 | 1 | — | 6 | 12 |
| Chronic hepatitis d | D019701 | — | — | 2 | 4 | 2 | — | 4 | 11 |
| Chronic hepatitis | D006521 | — | K73.9 | 4 | 4 | 2 | — | 3 | 11 |
| Liver diseases | D008107 | EFO_0001421 | K70-K77 | — | 1 | 1 | — | 1 | 3 |
| Digestive system diseases | D004066 | EFO_0000405 | K92.9 | — | 1 | 1 | — | — | 2 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Hepatitis b | D006509 | — | — | 1 | 3 | — | — | 1 | 4 |
| Chronic hepatitis b | D019694 | EFO_0004239 | B18.1 | 1 | 2 | — | — | 1 | 3 |
| Infections | D007239 | EFO_0000544 | — | 1 | 1 | — | — | 1 | 2 |
Indications Phases 1
No data
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Liver cirrhosis | D008103 | EFO_0001422 | K74.0 | — | — | — | — | 1 | 1 |
| Portal hypertension | D006975 | EFO_0000666 | K76.6 | — | — | — | — | 1 | 1 |
| Communicable diseases | D003141 | — | — | — | — | — | — | 1 | 1 |
| Disease | D004194 | EFO_0000408 | R69 | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Bulevirtide |
| INN | bulevirtide |
| Description | Bulevirtide, sold under the brand name Hepcludex, is an antiviral medication for the treatment of chronic hepatitis D (in the presence of hepatitis B).
|
| Classification | Protein |
| Drug class | peptides: antiviral peptides; antivirals |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | >8RQF:H|Heavy chain of Fab3
EISEVQLVESGGGLVQPGGSLRLSCAASGFNVSSSYIHWVRQAPGKGLEWVASISPYYSYTSYADSVKGRFTISADTSKN
TAYLQMNSLRAEDTAVYYCARYQYDYYYSYYAGLDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYF
PEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHT
>8RQF:L|Light chain of Fab3
SDIQMTQSPSSLSASVGDRVTITCRASQSVSSAVAWYQQKPGKAPKLLIYSASSLYSGVPSRFSGSRSGTDFTLTISSLQ
PEDFATYYCQQYRYSLITFGQGTKVEIKRTVAAPSVFIFPPSDSQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNS
QESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC |
Identifiers
| PDB | 8RQF |
| CAS-ID | 2012558-47-1 |
| RxCUI | — |
| ChEMBL ID | CHEMBL4297711 |
| ChEBI ID | — |
| PubChem CID | — |
| DrugBank | DB15248 |
| UNII ID | WKM56H3TLB (ChemIDplus, GSRS) |
Target
No data
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 935 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
54 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use